In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

Targets Key Regulator Of Neurotransmitters

 
• By Sushmita Panda
  
Neurocrine Biosciences
Neurocrine Biosciences reports further details of Phase II findings for its novel schizophrenia candidate. • Source: Alamy

More from Clinical Trials

More from Therapy Areas